Protagonist says JNJ-2113 met efficacy endpoints in psoriasis study

Protagonist Therapeutics (PTGX) announced topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor antagonist JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis. The trial achieved all primary and secondary efficacy endpoints. JNJ-2113 is being developed by Johnson & Johnson’s (JNJ) Janssen Biotech under Protagonist’s license and collaboration agreement with Janssen. A greater proportion of patients who received JNJ-2113 achieved PASI 75 as well as PASI 90 and PASI 100 compared to placebo, at week 16, the company said in a statement. Trial results for JNJ-2113 demonstrated a profile that supports its advancement into Phase 3 clinical development for moderate-to-severe plaque psoriasis in adult patients, it added.